• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 3. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 4. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Phthalimides

Chartarlactam A: A Comprehensive Overview

Chartarlactam A, also known by its CAS number 1528745-88-1, is a compound of significant interest in the fields of organic chemistry and pharmacology. This compound has garnered attention due to its unique structural properties and potential applications in drug development. Recent studies have shed light on its biological activities, making it a promising candidate for further exploration.

The Chartarlactam A structure is characterized by a complex arrangement of functional groups, including lactams and other heterocyclic moieties. These features contribute to its stability and reactivity, making it a valuable molecule for synthetic chemistry. Researchers have employed advanced spectroscopic techniques to elucidate its structure, confirming its uniqueness compared to other similar compounds.

One of the most notable aspects of Chartarlactam A is its bioactivity. Studies conducted in vitro have demonstrated its potential as an inhibitor of key enzymes involved in various pathological processes. For instance, recent research has highlighted its ability to modulate enzyme activity related to inflammation and oxidative stress, suggesting its role in anti-inflammatory and antioxidant therapies.

The synthesis of Chartarlactam A has been optimized through innovative methodologies, including microwave-assisted synthesis and catalytic processes. These advancements have not only improved the yield but also reduced the environmental impact of its production, aligning with green chemistry principles.

Moreover, Chartarlactam A has shown promise in preclinical models of diseases such as cancer and neurodegenerative disorders. Its ability to cross the blood-brain barrier makes it particularly interesting for central nervous system-related applications. Ongoing clinical trials are expected to provide further insights into its therapeutic potential.

In terms of applications, Chartarlactam A is being explored as a lead compound for drug discovery programs targeting various therapeutic areas. Its structural versatility allows for further modification to enhance potency and selectivity, opening avenues for personalized medicine.

Recent advancements in computational chemistry have also played a pivotal role in understanding the molecular interactions of Chartarlactam A. Molecular docking studies have provided valuable insights into its binding modes with target proteins, aiding in the design of more effective derivatives.

In conclusion, Chartarlactam A (CAS 1528745-88-1) stands out as a multifaceted compound with immense potential in both academic research and industrial applications. Its unique properties, coupled with ongoing research efforts, position it as a key player in the development of novel therapeutic agents.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)